Local Consolidative Therapy Shows No Survival Benefit After Dual Immunotherapy in Metastatic Lung Cancer
Source Summary
A clinical trial presented at the IASLC 2026 World Conference on Lung Cancer found that adding local consolidative therapy after induction treatment with nivolumab plus ipilimumab did not improve overall survival or progression-free survival in patients with metastatic non-small cell lung cancer. The finding applied to all patient groups studied, including those with oligometastatic disease.
Why it matters
This finding challenges the potential clinical benefit of combining local consolidative therapy with dual immunotherapy in metastatic lung cancer treatment.
